SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

NCT02830542 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Clostridium Difficile Infection

Interventions

DRUG: SER-262
DRUG: Placebo

Sponsor

Seres Therapeutics, Inc.

Collaborators

[object Object]